<p>, /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: <strong>HALO</strong>)（&#34;Halozyme&#34;）今天宣布选举 Jim Lang 为其董事会成员。Lang 先生在医疗保健、生命科学、商业服务和数据分析领域拥有超过 30 年的高管领导经验。</p>
<p>&#34;Jim 在构建和扩展创新医疗保健企业方面拥有丰富的经验，我们非常高兴欢迎他加入 Halozyme 董事会，&#34;首席执行官兼总裁 Helen Torley 博士表示。&#34;他的战略洞察力和通过并购推动增长的能力将成为我们实施增长战略、为包括合作伙伴、患者和股东在内的利益相关者创造有意义的新价值的巨大资产。&#34;</p>
<p>最近，Lang 先生担任 EVERSANA 的首席执行官，建立了全球领先的生命科学行业商业化服务提供商。作为首席执行官，Lang 先生通过收购超过二十家公司推动了公司的增长，并于 2025 年 8 月与 Waltz Health 合并。Lang 先生仍在 EVERSANA 的董事会任职。他还曾担任 Decision Resources Group（DRG）的首席执行官，在那里他通过显著扩展和收购将 DRG 转变为领先的医疗数据和分析公司。此前，Lang 先生是 Strategic Decision Group 的总裁，扩展了生命科学业务，后来将其出售给 IMS Health（现为 IQVIA）。</p>
<p>Lang 先生目前在临床阶段生物制药公司 Biovie, Inc.的董事会任职，担任审计委员会和提名与公司治理委员会的主席。他还在数字医疗科技公司 OptimizeRx Corporation 的董事会任职，担任薪酬委员会主席，并作为提名与公司治理委员会的成员。</p>
<p>&#34;我很荣幸加入 Halozyme 的董事会，&#34;Lang 先生表示。&#34;Halozyme 拥有坚实的基础和引人注目的增长战略。我期待与领导团队合作，帮助加速这一增长，并为我们的股东创造更大的价值。&#34;</p>
<p>Lang 先生获得新罕布什尔大学电气与计算机工程学士学位，并在达特茅斯学院塔克商学院获得 MBA 学位。</p>
<p><strong>关于 Halozyme</strong></p>
<p>Halozyme 是一家生物制药公司，致力于推进颠覆性解决方案，以改善患者体验和新兴及成熟疗法的结果。</p>
<p>作为 ENHANZE®药物递送技术的创新者，Halozyme 的专有酶 rHuPH20 提供了经过商业验证的解决方案，促进了注射药物和液体的皮下递送，减少了治疗负担，提高了便利性。ENHANZE®通过十种商业化产品影响了超过一百万患者的生活，覆盖超过 100 个全球市场，并已授权给包括罗氏、武田制药、辉瑞、强生、艾伯维、礼来、百时美施贵宝、argenx、ViiV Healthcare、中外制药、Acumen Pharmaceuticals 和 Merus N.V.等领先的制药和生物技术公司。</p>
<p>Halozyme 还在开发 Hypercon™，以扩展其药物递送技术组合的广度。Hypercon™是一种创新的微粒技术，预计将为药物和生物制剂的超浓缩设定新标准，可以减少相同剂量的注射体积，并扩大家庭和医疗提供者管理的机会。Hypercon™的加入增强了我们转变患者治疗体验的能力，使我们能够创造和递送高度浓缩的生物制剂，显著扩大了可以皮下递送的治疗范围。Hypercon™技术已授权给包括强生、礼来和 argenx 等领先的生物制药合作伙伴。</p>
<p>Halozyme 还开发、制造和商业化药物 - 设备组合产品，使用先进的自动注射器技术，旨在提高便利性、可靠性和耐受性，增强患者的舒适度和依从性。公司拥有两种专有商业产品 Hylenex®和 XYOSTED®，以及与 Teva Pharmaceuticals 和 Viatris Inc.的子公司 McDermott Laboratories Limited 的合作商业产品和持续开发项目。</p>
<p>Halozyme 总部位于加利福尼亚州圣地亚哥，在新泽西州尤因、明尼苏达州明尼通卡和马萨诸塞州波士顿设有办事处。明尼通卡也是其运营设施的所在地。</p>
<p>欲了解更多信息，请访问 www.halozyme.com，并在 LinkedIn 和 Twitter 上与我们联系。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿可能包含根据 1995 年《私人证券诉讼改革法案》及其修订版定义的前瞻性陈述。前瞻性陈述是指非历史事实的陈述，可能包括预测和估计及其基本假设，关于未来财务结果、事件、运营、服务、产品开发和潜力的计划、目标、意图和期望的陈述，以及关于 Halozyme 业务未来表现和增长的陈述。前瞻性陈述通常通过 “预计”、“预期”、“相信”、“打算”、“估计”、“计划”、“将会” 等类似表达来识别。尽管 Halozyme 相信这些前瞻性陈述中反映的期望是合理的，但投资者应注意，前瞻性信息和陈述受到各种风险和不确定性的影响，其中许多是难以预测的，并且通常超出 Halozyme 的控制，这可能导致实际结果和发展与前瞻性信息和陈述中表达的内容存在重大差异。实际结果可能因多种因素而与这些前瞻性陈述中的期望存在重大差异。这些可能导致差异的因素在公司最近提交的 10-K 表格年度报告和向证券交易委员会提交的 10-Q 表格季度报告中进行了更详细的讨论。Halozyme 没有义务更新或修订任何前瞻性陈述或本文件中包含的任何其他信息。</p>
<p><strong>联系方式</strong></p>
<p>Tram Bui</p>
<p>Halozyme</p>
<p>投资者关系与企业传播副总裁</p>
<p>609-359-3016</p>
<p>tbui@halozyme.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg"/></p>
<p>来源：Halozyme Therapeutics, Inc.</p>

奥洛兹美医疗

<p>Halozyme Therapeutics, Inc. 宣布选举 Jim Lang 为其董事会成员。Lang 在医疗保健和生命科学领域拥有超过 30 年的经验，预计将为公司提供战略见解并推动增长。他曾担任 EVERSANA 和 Decision Resources Group 的首席执行官。Lang 表达了对加入 Halozyme 的热情，旨在加速增长并提升股东价值</p>

<p>, /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: <strong>HALO</strong>) (&#34;Halozyme&#34;) today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: <strong>HALO</strong>)（&#34;Halozyme&#34;）今天宣布选举 Jim Lang 为其董事会成员。Lang 先生在医疗保健、生命科学、商业服务和数据分析领域拥有超过 30 年的高管领导经验。</p>
</div><p>&#34;Jim brings extensive experience in building and scaling innovative healthcare businesses, and we are delighted to welcome him to the Halozyme board,&#34; said Dr. Helen Torley, president and chief executive officer. &#34;His strategic insight and proven ability to drive growth, including through M&amp;A, will be a tremendous asset as we deliver on our growth strategy and create meaningful new value for our stakeholder, including partners, patients, and shareholders.&#34;</p>
<div class="lb-trans"><p>&#34;Jim 在构建和扩展创新医疗保健企业方面拥有丰富的经验，我们非常高兴欢迎他加入 Halozyme 董事会，&#34;首席执行官兼总裁 Helen Torley 博士表示。&#34;他的战略洞察力和通过并购推动增长的能力将成为我们实施增长战略、为包括合作伙伴、患者和股东在内的利益相关者创造有意义的新价值的巨大资产。&#34;</p>
</div><p>Most recently, Mr. Lang served as Chief Executive Officer of EVERSANA, building the leading global provider of commercialization services to the life sciences industry. As CEO, Mr. Lang led the company's growth through the acquisition of over twenty companies, culminating in its merger with Waltz Health in August 2025. Mr. Lang remains on EVERSANA's board. He also formerly served as CEO of Decision Resources Group (DRG), where he transformed DRG into a leading healthcare data and analytics firm through significant expansion and acquisitions. Previously, Mr. Lang was President of Strategic Decision Group, where he expanded the life sciences practice and later sold it to IMS Health (now IQVIA).</p>
<div class="lb-trans"><p>最近，Lang 先生担任 EVERSANA 的首席执行官，建立了全球领先的生命科学行业商业化服务提供商。作为首席执行官，Lang 先生通过收购超过二十家公司推动了公司的增长，并于 2025 年 8 月与 Waltz Health 合并。Lang 先生仍在 EVERSANA 的董事会任职。他还曾担任 Decision Resources Group（DRG）的首席执行官，在那里他通过显著扩展和收购将 DRG 转变为领先的医疗数据和分析公司。此前，Lang 先生是 Strategic Decision Group 的总裁，扩展了生命科学业务，后来将其出售给 IMS Health（现为 IQVIA）。</p>
</div><p>Mr. Lang currently serves on the board of Biovie, Inc., a clinical-stage biopharmaceutical company, where he chairs both the Audit Committee and the Nominating and Corporate Governance Committee. He also serves on the board of OptimizeRx Corporation, a digital healthcare technology company, acting as chair of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee.</p>
<div class="lb-trans"><p>Lang 先生目前在临床阶段生物制药公司 Biovie, Inc.的董事会任职，担任审计委员会和提名与公司治理委员会的主席。他还在数字医疗科技公司 OptimizeRx Corporation 的董事会任职，担任薪酬委员会主席，并作为提名与公司治理委员会的成员。</p>
</div><p>&#34;I am honored to join Halozyme's Board of Directors,&#34; said Mr. Lang. &#34;Halozyme has a strong foundation and a compelling strategy for growth. I look forward to working with the leadership team to help accelerate that growth and deliver even greater value to our shareholders.&#34;</p>
<div class="lb-trans"><p>&#34;我很荣幸加入 Halozyme 的董事会，&#34;Lang 先生表示。&#34;Halozyme 拥有坚实的基础和引人注目的增长战略。我期待与领导团队合作，帮助加速这一增长，并为我们的股东创造更大的价值。&#34;</p>
</div><p>Mr. Lang earned his B.S. in in Electrical and Computer Engineering from the University of New Hampshire and his MBA from the Tuck School of Business at Dartmouth.</p>
<div class="lb-trans"><p>Lang 先生获得新罕布什尔大学电气与计算机工程学士学位，并在达特茅斯学院塔克商学院获得 MBA 学位。</p>
</div><p><strong>About Halozyme</strong></p>
<div class="lb-trans"><p><strong>关于 Halozyme</strong></p>
</div><p>Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.</p>
<div class="lb-trans"><p>Halozyme 是一家生物制药公司，致力于推进颠覆性解决方案，以改善患者体验和新兴及成熟疗法的结果。</p>
</div><p>As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.</p>
<div class="lb-trans"><p>作为 ENHANZE®药物递送技术的创新者，Halozyme 的专有酶 rHuPH20 提供了经过商业验证的解决方案，促进了注射药物和液体的皮下递送，减少了治疗负担，提高了便利性。ENHANZE®通过十种商业化产品影响了超过一百万患者的生活，覆盖超过 100 个全球市场，并已授权给包括罗氏、武田制药、辉瑞、强生、艾伯维、礼来、百时美施贵宝、argenx、ViiV Healthcare、中外制药、Acumen Pharmaceuticals 和 Merus N.V.等领先的制药和生物技术公司。</p>
</div><p>Halozyme is also developing Hypercon™ to expand the breadth of its drug delivery technology portfolio. Hypercon™ is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon™ enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson &amp; Johnson, Eli Lilly, and argenx.</p>
<div class="lb-trans"><p>Halozyme 还在开发 Hypercon™，以扩展其药物递送技术组合的广度。Hypercon™是一种创新的微粒技术，预计将为药物和生物制剂的超浓缩设定新标准，可以减少相同剂量的注射体积，并扩大家庭和医疗提供者管理的机会。Hypercon™的加入增强了我们转变患者治疗体验的能力，使我们能够创造和递送高度浓缩的生物制剂，显著扩大了可以皮下递送的治疗范围。Hypercon™技术已授权给包括强生、礼来和 argenx 等领先的生物制药合作伙伴。</p>
</div><p>Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.</p>
<div class="lb-trans"><p>Halozyme 还开发、制造和商业化药物 - 设备组合产品，使用先进的自动注射器技术，旨在提高便利性、可靠性和耐受性，增强患者的舒适度和依从性。公司拥有两种专有商业产品 Hylenex®和 XYOSTED®，以及与 Teva Pharmaceuticals 和 Viatris Inc.的子公司 McDermott Laboratories Limited 的合作商业产品和持续开发项目。</p>
</div><p>Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.</p>
<div class="lb-trans"><p>Halozyme 总部位于加利福尼亚州圣地亚哥，在新泽西州尤因、明尼苏达州明尼通卡和马萨诸塞州波士顿设有办事处。明尼通卡也是其运营设施的所在地。</p>
</div><p>For more information, visit www.halozyme.com and connect with us on LinkedIn and Twitter.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.halozyme.com，并在 LinkedIn 和 Twitter 上与我们联系。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words &#34;expects&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;plans&#34;, &#34;will be&#34; and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.</p>
<div class="lb-trans"><p>本新闻稿可能包含根据 1995 年《私人证券诉讼改革法案》及其修订版定义的前瞻性陈述。前瞻性陈述是指非历史事实的陈述，可能包括预测和估计及其基本假设，关于未来财务结果、事件、运营、服务、产品开发和潜力的计划、目标、意图和期望的陈述，以及关于 Halozyme 业务未来表现和增长的陈述。前瞻性陈述通常通过 “预计”、“预期”、“相信”、“打算”、“估计”、“计划”、“将会” 等类似表达来识别。尽管 Halozyme 相信这些前瞻性陈述中反映的期望是合理的，但投资者应注意，前瞻性信息和陈述受到各种风险和不确定性的影响，其中许多是难以预测的，并且通常超出 Halozyme 的控制，这可能导致实际结果和发展与前瞻性信息和陈述中表达的内容存在重大差异。实际结果可能因多种因素而与这些前瞻性陈述中的期望存在重大差异。这些可能导致差异的因素在公司最近提交的 10-K 表格年度报告和向证券交易委员会提交的 10-Q 表格季度报告中进行了更详细的讨论。Halozyme 没有义务更新或修订任何前瞻性陈述或本文件中包含的任何其他信息。</p>
</div><p><strong>Contact</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p>Tram Bui</p>
<div class="lb-trans"><p>Tram Bui</p>
</div><p>Halozyme</p>
<div class="lb-trans"><p>Halozyme</p>
</div><p>VP, Investor Relations and Corporate Communications</p>
<div class="lb-trans"><p>投资者关系与企业传播副总裁</p>
</div><p>609-359-3016</p>
<div class="lb-trans"><p>609-359-3016</p>
</div><p>tbui@halozyme.com</p>
<div class="lb-trans"><p>tbui@halozyme.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg"/></p>
<p>SOURCE Halozyme Therapeutics, Inc.</p>
<div class="lb-trans"><p>来源：Halozyme Therapeutics, Inc.</p>
</div>

吉姆·朗被选为奥洛兹美医疗董事会成员 | HALO 股票新闻